Recent studies [2, 3, 6] showed the detection of clinically relevant oncologic driver mutations like e.g. KRAS, EGFR or secondary EGFR T790M resistance mutations in ctDNA with nearly maximal specificity (> 95%) compared to tumor tissue as the gold standard in cancer diagnostics. This evidence concerns the gene KRAS and neoplasm.